Annual Accounts Receivable
N/A
December 1, 2024
Summary
- EW annual accounts receivable is not available.
Performance
EW Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly Accounts Receivable
N/A
December 1, 2024
Summary
- EW quarterly accounts receivable is not available.
Performance
EW Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Accounts Receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
EW Accounts Receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | - |
| 3 y3 years | - | - |
| 5 y5 years | - | - |
EW Accounts Receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | ||||
| 5 y | 5-year | ||||
| alltime | all time |
Edwards Lifesciences Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $716.00 M(-8.0%) |
| Jun 2024 | - | $778.30 M(-4.8%) |
| Mar 2024 | - | $817.60 M(+5.5%) |
| Dec 2023 | $775.10 M(+20.5%) | $775.10 M(+4.8%) |
| Sep 2023 | - | $739.80 M(-1.9%) |
| Jun 2023 | - | $754.40 M(+5.1%) |
| Mar 2023 | - | $717.70 M(+11.6%) |
| Dec 2022 | $643.00 M(+10.4%) | $643.00 M(+4.0%) |
| Sep 2022 | - | $618.10 M(-2.9%) |
| Jun 2022 | - | $636.40 M(+0.0%) |
| Mar 2022 | - | $636.30 M(+9.3%) |
| Dec 2021 | $582.20 M(+13.1%) | $582.20 M(-3.1%) |
| Sep 2021 | - | $600.60 M(-6.2%) |
| Jun 2021 | - | $640.50 M(+9.2%) |
| Mar 2021 | - | $586.60 M(+14.0%) |
| Dec 2020 | $514.60 M(-5.3%) | $514.60 M(-6.4%) |
| Sep 2020 | - | $549.70 M(-3.2%) |
| Jun 2020 | - | $567.90 M(-2.9%) |
| Mar 2020 | - | $585.10 M(+7.6%) |
| Dec 2019 | $543.60 M(+19.0%) | $543.60 M(-4.6%) |
| Sep 2019 | - | $570.00 M(-6.5%) |
| Jun 2019 | - | $609.60 M(+5.5%) |
| Mar 2019 | - | $578.00 M(+26.5%) |
| Dec 2018 | $456.90 M(+4.1%) | $456.90 M(+7.8%) |
| Sep 2018 | - | $423.80 M(-1.8%) |
| Jun 2018 | - | $431.40 M(+6.1%) |
| Mar 2018 | - | $406.60 M(-7.3%) |
| Dec 2017 | $438.70 M(+20.0%) | $438.70 M(-7.6%) |
| Sep 2017 | - | $475.00 M(-7.0%) |
| Jun 2017 | - | $510.70 M(+0.1%) |
| Mar 2017 | - | $510.20 M(+39.6%) |
| Dec 2016 | $365.50 M(+15.9%) | $365.50 M(-19.5%) |
| Sep 2016 | - | $454.20 M(+6.7%) |
| Jun 2016 | - | $425.80 M(+9.6%) |
| Mar 2016 | - | $388.50 M(+23.2%) |
| Dec 2015 | $315.40 M(+9.5%) | $315.40 M(-6.8%) |
| Sep 2015 | - | $338.40 M(-3.6%) |
| Jun 2015 | - | $351.00 M(+1.7%) |
| Mar 2015 | - | $345.30 M(+19.9%) |
| Dec 2014 | $288.00 M(-4.8%) | $288.00 M(-10.8%) |
| Sep 2014 | - | $322.90 M(-1.4%) |
| Jun 2014 | - | $327.50 M(+7.3%) |
| Mar 2014 | - | $305.10 M(+0.9%) |
| Dec 2013 | $302.50 M(-5.8%) | $302.50 M(-7.7%) |
| Sep 2013 | - | $327.80 M(-4.1%) |
| Jun 2013 | - | $341.80 M(+3.7%) |
| Mar 2013 | - | $329.70 M(+2.7%) |
| Dec 2012 | $321.10 M | $321.10 M(-1.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2012 | - | $325.40 M(-3.3%) |
| Jun 2012 | - | $336.40 M(-3.0%) |
| Mar 2012 | - | $346.70 M(+22.2%) |
| Dec 2011 | $283.80 M(+2.3%) | $283.80 M(-18.2%) |
| Sep 2011 | - | $346.80 M(-4.8%) |
| Jun 2011 | - | $364.10 M(+2.8%) |
| Mar 2011 | - | $354.20 M(+27.7%) |
| Dec 2010 | $277.30 M(+11.2%) | $277.30 M(-8.6%) |
| Sep 2010 | - | $303.40 M(+3.2%) |
| Jun 2010 | - | $294.00 M(+5.5%) |
| Mar 2010 | - | $278.60 M(+11.7%) |
| Dec 2009 | $249.40 M(+33.9%) | $249.40 M(-11.1%) |
| Sep 2009 | - | $280.50 M(+2.2%) |
| Jun 2009 | - | $274.50 M(+7.3%) |
| Mar 2009 | - | $255.80 M(+37.3%) |
| Dec 2008 | $186.30 M(+60.9%) | $186.30 M(-12.8%) |
| Sep 2008 | - | $213.60 M(+23.3%) |
| Jun 2008 | - | $173.30 M(+11.6%) |
| Mar 2008 | - | $155.30 M(+34.1%) |
| Dec 2007 | $115.80 M(+3.9%) | $115.80 M(-15.3%) |
| Sep 2007 | - | $136.70 M(-0.5%) |
| Jun 2007 | - | $137.40 M(+6.3%) |
| Mar 2007 | - | $129.30 M(+16.0%) |
| Dec 2006 | $111.50 M(-5.9%) | $111.50 M(-14.4%) |
| Sep 2006 | - | $130.20 M(-2.6%) |
| Jun 2006 | - | $133.70 M(+8.7%) |
| Mar 2006 | - | $123.00 M(+3.8%) |
| Dec 2005 | $118.50 M(+13.8%) | $118.50 M(-5.9%) |
| Sep 2005 | - | $125.90 M(+0.8%) |
| Jun 2005 | - | $124.90 M(-2.2%) |
| Mar 2005 | - | $127.70 M(+22.7%) |
| Dec 2004 | $104.10 M(+6.8%) | $104.10 M(-8.0%) |
| Sep 2004 | - | $113.20 M(+2.8%) |
| Jun 2004 | - | $110.10 M(-3.0%) |
| Mar 2004 | - | $113.50 M(+16.4%) |
| Dec 2003 | $97.50 M(+10.4%) | $97.50 M(-15.7%) |
| Sep 2003 | - | $115.60 M(-7.1%) |
| Jun 2003 | - | $124.40 M(-0.4%) |
| Mar 2003 | - | $124.90 M(+41.4%) |
| Dec 2002 | $88.30 M(+3.5%) | $88.30 M(-22.0%) |
| Sep 2002 | - | $113.20 M(-1.0%) |
| Jun 2002 | - | $114.40 M(+4.7%) |
| Mar 2002 | - | $109.30 M(+28.1%) |
| Dec 2001 | $85.30 M(-20.3%) | $85.30 M(-28.3%) |
| Sep 2001 | - | $119.00 M(+2.2%) |
| Jun 2001 | - | $116.40 M(-14.5%) |
| Mar 2001 | - | $136.20 M(+27.3%) |
| Dec 2000 | $107.00 M(-19.5%) | $107.00 M |
| Dec 1999 | $133.00 M | - |
FAQ
- What is the all time high annual accounts receivable for Edwards Lifesciences?
- What is the all time high quarterly accounts receivable for Edwards Lifesciences?
What is the all time high annual accounts receivable for Edwards Lifesciences?
Edwards Lifesciences all-time high annual accounts receivable is $775.10 M
What is the all time high quarterly accounts receivable for Edwards Lifesciences?
Edwards Lifesciences all-time high quarterly accounts receivable is $817.60 M